In the future, potential therapeutic targets to reduce circulating NETs in BD may include ROS scavengers like N‐acetylcysteine, PAD inhibitors like Cl‐amidine and DNase used in SLE195, 196 and RA, which have been shown to be effective.197, 198. This evidence concerns the gene PADI4 and rheumatoid arthritis.